In Brief: Bayer Cipro
Executive Summary
Bayer Cipro: Ciprofloxacin I.V. approved Aug. 7 for empirical therapy in febrile neutropenic patients in formulations of 1% solution, 2% solution in 5% dextrose and .2% solution in .9% sodium chloride. User fee goal date for NDAs 19-847/S-015, 19-857/S-017 and 19-858/S-015 was Aug. 9...